AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31918984
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval exercise (HIIE) with 30% evening basal insulin reduction
Trial: 31358401
Drug: Red-blue irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red-blue irradiation treatment
Trial: 25333776
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg twice daily for 26 weeks
Trial: 23345636
Drug: Shoulder taping
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shoulder taping and conventional treatment
Trial: 23345636
Drug: Sham taping
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham taping and conventional treatment
Trial: 12859140
Drug: Dalbavancin; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin; specific dosage and duration not mentioned.
Trial: 11113028
Drug: Antipyretic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipyretic therapy (nonsteroidal anti-inflammatory drugs)
Trial: 11113028
Drug: Antipyretic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipyretic therapy
Trial: 1642652
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (AZA + MTX)
Trial: 6430063
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate 300 mg t.i.d.
Trial: 27220523
Drug: Tablet PC
RxNorm normalized name: PCS-499
DrugBank: PCS-499 (DB15122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet PC questionnaire
Trial: 27220523
Drug: Both methods
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both methods (tablet PC and paper)
Trial: 22830517
Drug: LT peel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT peel (lidocaine 70 mg/g and tetracaine 70 mg/g)
Trial: 20586916
Drug: Endovascular therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapies (thrombolytic therapy)
Trial: 12608943
Drug: Alendronate treatment
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate treatment at a dose of 10 mg/day for 12 months
Trial: 10509846
Drug: Sparfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (400 mg on day 1, 200 mg daily on days 2‐4)
Trial: 10509846
Drug: Terfenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (60 mg BID)
Trial: 10509846
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sparfloxacin and terfenadine
Trial: 1940190
Drug: Low-dose antacid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antacid (AA, Supralox, 1 tablet three times a day 1 h a.c. and 2 tablets at bedtime, with acid binding capacity of 225 mEq)
Trial: 1940190
Drug: Low-dose antacid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antacid (AA)
Trial: 6757394
Drug: Work-site (WS)
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Work-site (WS) treatment program
Trial: 29516455
Drug: Dolphin Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolphin Assisted Therapy (DAT)
Trial: 27343343
Drug: Home-based upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based upper limb training program for 8 weeks, twice a week
Trial: 18589766
Drug: Naoxinqing tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoxinqing tablet
Trial: 18589766
Drug: Naoxinqing tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoxinqing tablet + half dose Simvastatin
Trial: 18589766
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose Simvastatin
Trial: 6666645
Drug: nomifensine 25-50
RxNorm normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nomifensine 25-50 mg taken three times daily
Trial: 6666645
Drug: Motipress (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motipress (1.5 mg fluphenazine with 30 mg nortriptyline) taken once daily
Trial: 27932449
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate 200 mg twice daily
Trial: 19090898
Drug: Heparin lock
RxNorm normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin lock six times a week
Trial: 19090898
Drug: Heparin lock
RxNorm normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin lock three times a week
Trial: 16542788
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (CT) with radiation therapy (RT)
Trial: 16542788
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (CT) followed by radiation therapy (RT)
Trial: 9101194
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with intraoperative application of 0.1 mg/ml mitomycin C
Trial: 3790403
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg biphasic release tablet of nifedipine
Trial: 22437967
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level fluence 810 nm (15 Joules/cm(2)) laser diode therapy
Trial: 15853819
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with PTU (100 mg twice a day), propranolol (40 mg twice a day), and cholestyramine (4 g twice a day) for 4 weeks
Trial: 15853819
Drug: PTU (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTU (100 mg twice a day) and propranolol (40 mg twice a day) for 4 weeks
Trial: 10713872
Drug: N2O (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N2O (20, 40, 60, and 70% inhaled at 20-min intervals)
Trial: 10713872
Drug: Ketamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.4 mg kg‐1 + 1.0 mg kg‐1h‐1)
Trial: 2011259
Drug: Pramiracetam (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramiracetam (up to 4,000 mg)
Trial: 31251351
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) treatment at a dosage of 20 mg/kg before cardiac catheterization.
Trial: 27886686
Drug: Preoperative warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative warfarin therapy
Trial: 27886686
Drug: Postoperative warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative warfarin therapy
Trial: 25488505
Drug: Treatment Control
RxNorm normalized name: SALICYLIC ACID 2 g in 100 mL TOPICAL LOTION [Lqd ACNE BLEMISH TREATMENT control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Control Condition (TCC)
Trial: 17076695
Drug: S-3304 800
RxNorm normalized name: S-3304
DrugBank: S-3304 (DB12149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-3304 800 mg
Trial: 17076695
Drug: S-3304 1600
RxNorm normalized name: POLYQUATERNIUM-4 (1600 MPA.S AT 2%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-3304 1600 mg
Trial: 17076695
Drug: S-3304 2400
RxNorm normalized name: S-3304
DrugBank: S-3304 (DB12149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-3304 2400 mg
Trial: 17076695
Drug: S-3304 3200
RxNorm normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S-3304 3200 mg
Trial: 17076695
Drug: S-3304 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-3304 (all doses)
Trial: 9487416
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (glucose 25g i.v. with insulin 10 units i.v.)
Trial: 9487416
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (50 mmol of 8.4% sodium bicarbonate infusion)
Trial: 9487416
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C (0.5mg of salbutamol i.v. in 50mls 5% dextrose)
Trial: 9487416
Drug: Treatment D
RxNorm normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment D (combination of treatments A and B)
Trial: 9487416
Drug: Treatment E
RxNorm normalized name: Benzoyl Peroxide 10% Topical application Cream [ACNE TREATMENT EXTRA STRENGTH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment E (combination of treatment B and C)
Trial: 9487416
Drug: Treatment F
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment F (combination of treatments A and C)
Trial: 9487416
Drug: Treatment G
RxNorm normalized name: VanaLice Lice Killing Treatment Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment G (combination of treatments A, B, and C)
Trial: 8368735
Drug: VMCL plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMCL plus low dose cyclophosphamide
Trial: 8368735
Drug: VMCL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMCL treatment
Trial: 3530861
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) tablets
Trial: 21551317
Drug: Extended-release (ER)
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release (ER) propiverine 45 mg
Trial: 21551317
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) propiverine 30 mg
Trial: 21551317
Drug: Fat-rich meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-rich meal before administration of propiverine
Trial: 7630148
Drug: CNS 1102
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CNS 1102 (2 mg)
Trial: 2774588
Drug: Cepharanthine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cepharanthine (50 mg intravenously every day during postoperative chemotherapy)
Trial: 2774588
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no administration of Cepharanthine)
Trial: 303115
Drug: Benoxaprofen 100
RxNorm normalized name: (±)-benoxaprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen 100 mg
Trial: 303115
Drug: Benoxaprofen 200
RxNorm normalized name: fenoprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen 200 mg
Trial: 303115
Drug: Benoxaprofen 400
RxNorm normalized name: fenoprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen 400 mg
Trial: 303115
Drug: Benoxaprofen 25
RxNorm normalized name: (±)-benoxaprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen 25 mg every 24 hours
Trial: 303115
Drug: Benoxaprofen 50
RxNorm normalized name: (±)-benoxaprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen 50 mg every 24 hours
Trial: 303115
Drug: Benoxaprofen 100
RxNorm normalized name: (±)-benoxaprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen 100 mg every 12 hours
Trial: 303115
Drug: Benoxaprofen (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen (various doses)
Trial: 31812127
Drug: Carbamazepine controlled-release
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine controlled-release (carbamazepine-CR)
Trial: 24979880
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate 80 mg/kg
Trial: 11322638
Drug: Orengedoku‐to (Huanglian‐Jie‐Du‐Tang)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orengedoku‐to (Huanglian‐Jie‐Du‐Tang) granules (7.5 g daily)
Trial: 11322638
Drug: Kakkon‐to (Ge‐Gen‐Tang)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kakkon‐to (Ge‐Gen‐Tang) granules (7.5 g daily)
Trial: 11322638
Drug: Sairei‐to (Cai‐Ling‐Tang)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sairei‐to (Cai‐Ling‐Tang) granules (9.0 g daily)
Trial: 11322638
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no herbal medicine)
Trial: 7524798
Drug: Piperacillin/tazobactam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (3 g/375 mg every six hours)
Trial: 7524798
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg every six hours) plus gentamicin (2.5 mg to 5.0 mg/kg every eight to 12 hours)
Trial: 26860809
Drug: Oligofructose-enriched inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oligofructose-enriched inulin (10g daily for 2 months)
Trial: 24627419
Drug: Mipomersen 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 30 mg once daily
Trial: 24627419
Drug: Mipomersen 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 70 mg 3 times weekly
Trial: 30500603
Drug: Mipomersen 200
RxNorm normalized name: mipomersen 200 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 200 mg once weekly
Trial: 15746682
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (IMN) 40 mg in addition to gemeprost 1 mg up to 3 times daily for 2 days
Trial: 15746682
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (IMN) 40 mg in addition to gemeprost
Trial: 1307234
Drug: Vitamin supplement
RxNorm normalized name: Vitamin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplement (containing 12 vitamins including 0.8 mg of folic acid)
Trial: 7970646
Drug: Trace-element supplement
RxNorm normalized name: chromic chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trace-element supplement (containing copper, manganese, zinc, and a very low dose of vitamin C)
Trial: 6364774
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 IU, d‐alpha‐tocopheryl acetate, by mouth twice daily for 20 weeks)
Trial: 6364774
Drug: Placebo (by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (by mouth twice daily for 20 weeks)
Trial: 19827527
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with quinapril (23.3 ± 9.8 mg) and indapamide (1.5 mg)
Trial: 16670131
Drug: Very-low-calorie diets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-calorie diets, pharmacotherapy, and lifestyle change
Trial: 10325261
Drug: Trimegestone (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimegestone (0.05, 0.1, 0.25 and 0.5 mg per day) with continuous micronized oestradiol 2 mg daily for six treatment cycles
Trial: 10325261
Drug: Trimegestone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimegestone (various doses)
Trial: 8609099
Drug: Oral slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral slow-release albuterol 8 mg, twice-daily (b.i.d.)
Trial: 8609099
Drug: Oral slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral slow-release albuterol 8 mg, once daily at night
Trial: 7064012
Drug: Furosemide 80
RxNorm normalized name: furosemide 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 80 mg
Trial: 7064012
Drug: Tizolemide 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizolemide 100 mg
Trial: 6388334
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (Tetracyclines)
Trial: 28884308
Drug: Usual pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual pharmacological therapy plus 2-week spa therapy
Trial: 28884308
Drug: Usual pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual pharmacological therapy alone
Trial: 24019259
Drug: KB001 3
RxNorm normalized name: KB001
DrugBank: KB001 (DB05222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KB001 3 mg/kg
Trial: 24019259
Drug: KB001 10
RxNorm normalized name: KB001
DrugBank: KB001 (DB05222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KB001 10 mg/kg
Trial: 20160047
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg lersivirine plus 20 ml Maalox Max
Trial: 20160047
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg lersivirine alone
Trial: 18553042
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1,000 mg)
Trial: 12847386
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg in isotonic saline)
Trial: 16021874
Drug: alternating treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alternating treatment (stavudine/didanosine for 12 weeks followed by zidovudine/lamivudine)
Trial: 2064702
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 ml saline solution NaCl 0.9%)
Trial: 20558907
Drug: Sonazoid (ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonazoid (ultrasound contrast agent)
Trial: 12838194
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose regimen (10,000 IU 3 times per week)
Trial: 7743787
Drug: Stepped-care regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care regimen (initial treatment with niacin followed by other agents if needed)
Trial: 7743787
Drug: Lovastatin (HMG-CoA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (HMG-CoA reductase inhibitor)
Trial: 2289390
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg rectal suppository one hour pre-operatively)
Trial: 28673219
Drug: 1,200 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 ml carbohydrate solution leading up to admission (up until two hours pre-colonoscopy)
Trial: 21477333
Drug: Glandosane (G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glandosane (G)
Trial: 21477333
Drug: Both saliva
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both saliva substitutes (SN and G)
Trial: 15599323
Drug: Daclizumab 1
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 1 mg/kg on day 0 and every 14 days for five doses (group 1, n = 30)
Trial: 15599323
Drug: Daclizumab 2
RxNorm normalized name: daclizumab 25 MG per 5 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 2 mg/kg on day 0 and on the day of discharge (group 2, n = 22)
Trial: 15599323
Drug: Daclizumab 1
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 1 mg/kg (group 1)
Trial: 15599323
Drug: Daclizumab 2
RxNorm normalized name: daclizumab 25 MG per 5 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 2 mg/kg (group 2)
Trial: 9165608
Drug: Desmopressin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin treatment (both intravenous and oral)
Trial: 29363373
Drug: Short-course low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Short-course low-dose oral prednisolone (tapering doses over 2 weeks)
Trial: 29363373
Drug: Short-course low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Short-course low-dose oral prednisolone
Trial: 28481068
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (EPN) in group A
Trial: 28481068
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid therapy in group B